News Archive of Clinical Trials - Business Wire

STENTYS Self-Apposing® Stent Demonstrates Lowest Mortality Rate Among Large Heart Attack Trials03-09-13
Enzo Biochem Schedules Teleconference to Discuss Second Quarter Results on March 13, 2013 at 8:30 AM E.T.03-08-13
Research and Markets: Thromboembolism Global Clinical Trials Review, H1, 201303-08-13
RegeneRx Receives Notice of Allowance for 2nd U.S. Heart Patent03-08-13
Trevena to present results of TRV027 Phase 2a Study in Patients with Advanced Heart Failure03-08-13
Retrophin to Present at 25th Annual ROTH Conference03-08-13
Dyax Announces Management Change03-08-13
Research and Markets: Strabismus Global Clinical Trials Review, H1, 201303-08-13
Research and Markets: Gestational Diabetes Global Clinical Trials Review, H1, 201303-08-13
St. Jude Medical Announces First Implant in Pivotal Phase of Clinical Trial Evaluating AMPLATZER Cardiac Plug for the Prevention of Stroke in Patients with Atrial Fibrillation03-08-13
Research and Markets: Aortic Aneurysm Global Clinical Trials Review, H1, 201303-08-13
Resumen: Avinger da a conocer a los principales investigadores del próximo ensayo VISION03-08-13
Samenvatting: Biogen Idec presenteert nieuwe data neurologisch portfolio op AAN-jaarvergadering03-08-13
Research and Markets: Regurgitation Global Clinical Trials Review, H1, 201303-08-13
Research and Markets: Atopic Dermatitis Global Clinical Trials Review, H1, 201303-08-13
Research and Markets: Asthma Global Clinical Trials Review, H1, 201303-08-13
Samenvatting: Avinger kondigt primaire onderzoekers aan voor aanstaande VISION-studie03-08-13
Biogen Idec stellt neue Ergebnisse zu vielfältigem neurologischen Portfolio auf der 65. AAN-Jahrestagung vor03-08-13
Bristol-Myers Squibb Announces Dividend03-07-13
Anacor Pharmaceuticals Announces 2012 Fourth Quarter and Year End Financial Results Conference Call and Webcast03-07-13
Biovest Files Recapitalization Plan to Strengthen Balance Sheet and Advance Commercialization Strategy for BiovaxID? Cancer Vaccine03-07-13
Bio-Path Holdings Begins Enrollment in Fifth Cohort of Phase I Clinical Trial of Lead Product Candidate Liposomal Grb-2 in Leukemias03-07-13
Gilead anuncia los resultados completos de fase 2 de 24 semanas para el tratamiento del VIH con comprimido único de una sola dosis diaria que contiene el profármaco novel tenofovir alafenamide (TAF)03-07-13
Cytori Reports 2012 Business and Financial Results; Provides Outlook for 201303-07-13
Advanced Cell Technology Announces Fourth-Quarter and Year-end Results03-07-13
Gilead veröffentlicht Gesamtergebnisse der 24-wöchigen HIV-Behandlung der Phase 2 mit einmal täglich eingenommenem Einzeltabletten-Kombipräparat, das neuartiges Prodrug-Tenofoviralafenamid (TAF) enthält03-07-13
Satellite Healthcare Celebrates National Kidney Month, World Kidney Day with Free Blood Pressure Screenings03-07-13
Data from First Clinical Trial of GGF2 in Heart Failure Presented at the American College of Cardiology 62nd Annual Scientific Session03-07-13
TRADE NEWS: Agilent Technologies and Applied Proteomics Will Collaborate to Maximize Capabilities of Highly Multiplexed Protein Assays03-07-13
Gilead ha comunicato i risultati completi a 24 settimane dello studio di fase II per il regime monocompressa a somministrazione monogiornaliera per il trattamento dell'infezione da HIV contenente il nuovo profarmaco Tenofovir Alafenamide (TAF)03-07-13
CFS Clinical Launches Business Intelligence Platform Improving Decision-Making for Clinical Trials03-07-13
Protalex to Continue Phase 1b Trial of PRTX-100 in Patients with Active Rheumatoid Arthritis Following Data Safety Monitoring Committee Review03-07-13
Riassunto: Avinger annuncia gli investigatori primari per la prossima sperimentazione di VISION03-07-13
Avinger gibt Prüfärzte für bevorstehende VISION-Studie bekannt03-07-13
Avinger Announces Primary Investigators for Upcoming VISION Trial03-07-13
Avinger annonce les investigateurs principaux de son prochain essai VISION03-07-13
Magellan Pharmacy Solutions? Whole Health RxSM Delivers a Total Health Approach to Integrate Prescribing Practices03-07-13
Capricor, Inc. Appoints Anthony Davies, Ph.D., Chief Technology Officer03-07-13
ADMA Biologics Commences Pivotal Phase III Clinical Study of RI-002 in PIDD Patients03-07-13
OncoMed Pharmaceuticals Initiates Phase 1 Clinical Trial of Anti-Cancer Stem Cell Therapeutic OMP-52M51 (Anti-Notch1) in Solid Tumors03-07-13
Acceleron Initiates Phase 2 Study of ACE-536 to Treat Patients with Beta-Thalassemia03-07-13
Biogen Idec presenta nuevos datos sobre sus diversas carteras neurológicas durante el 65º Congreso Anual de la AAN03-07-13
Biogen Idec presenterà i nuovi dati relativi al suo portafoglio di prodotti neurologici durante il 65° Meeting annuale dell'Accademia americana di neurologia03-07-13
Research and Markets: Hypotension Global Clinical Trials Review, H1, 201303-07-13
Hi-Tech Pharmacal Reports Sales of $64.3 Million and EPS of $0.43 for the Third Quarter Ended January 31, 201303-07-13
Arrowhead to Host Analyst Event in New York to Discuss RNAi-based Hepatitis B Candidate ARC-52003-07-13
Nevro Corp. Closes $48 Million in New Financing03-07-13
Gilead kondigt de volledige fase 2 resultaten na 24 weken aan van eenmaal daags, uit één tablet bestaande hiv-behandeling met nieuw prodrug tenofovir alafenamide (TAF)03-07-13
Gilead annonce les résultats complets de 24 semaines d'une étude de Phase 2 pour un régime posologique à comprimé unique à prise quotidienne contenant le nouveau promédicament ténofovir alafénamide (TAF) pour le traitement de l'infection...03-07-13
Otsuka Advancing Rapidly in Central Nervous System Disorders; Expanding Existing Collaboration with Lundbeck03-07-13
Biogen Idec présente de nouvelles données sur ses divers portefeuilles neurologiques lors de la 65e conférence annuelle de l'AAN03-07-13
InSite Vision Announces Date for Annual Shareholder Meeting03-06-13
LabCorp is Scheduled to Present at the Barclays Capital 2013 Global Healthcare Conference03-06-13
ADMA Biologics Reports 2012 Year End Financial and Operational Results03-06-13
Navidea Announces Fourth Quarter and Full-Year 2012 Results03-06-13
Furiex Reports Fourth Quarter and Full Year 2012 Financial Results03-06-13
Advaxis Provides Business Outlook for 201303-06-13
Biogen Idec to Present New Data on Diverse Neurological Portfolio at 65th AAN Annual Meeting03-06-13
NanoString Technologies Presents Positive Results from Multisite Analytical Validation Study of Prosigna? Breast Cancer Prognostic Gene Signature Assay03-06-13
Transgenomic to Hold Fourth Quarter Financial Results Conference Call on March 13, 201303-06-13
Lantheus Medical Imaging Announces Appointment of Cesare Orlandi, M.D., as New Chief Medical Officer03-06-13
BIND Biosciences to Present at Upcoming 2013 Scientific Conferences03-06-13
First Patient Enrolled in Third Phase III Study of Oral Laquinimod for Relapsing-Remitting Multiple Sclerosis03-06-13
Osiris Therapeutics Reports Fourth Quarter and Full Year 2012 Financial Results03-06-13
Stephen Sherwin, M.D., Joins Verastem Board of Directors03-06-13
Zalicus Reports Financial Results for the Fourth Quarter and Year End 201203-06-13
Programm der EuroMedtech? 2013 mit Führungskräften aus dem Bereich Medizintechnik03-06-13
Santarus and VeroScience Announce Publication of AACE Expert Panel Recommendations for CYCLOSET® (bromocriptine mesylate) for the Management of Type 2 Diabetes03-06-13
Le programme EuroMedtech? 2013 fait intervenir des cadres exécutifs du secteur des appareils médicaux03-06-13
Infinity Provides Company Update and Reports Full-Year 2012 Financial Results03-05-13
Research and Markets: Fabry Disease Global Clinical Trials Review, H1, 2013 Out Now03-05-13
Research and Markets: Diabetic Gastroparesis Global Clinical Trials Review, H1, 2013 Provides Briefing Pertaining To the Number of Trials for the Key Drugs03-05-13
Research and Markets: Malnutrition Global Clinical Trials Review, H1, 2013 Features Players Abbott Nutrition, Danone Research B.V. and Nutricia UK Ltd03-05-13
Riassunto: I manager del settore dei dispositivi medicali protagonisti di EuroMedtech? 201303-05-13
Gilead Announces Full 24-Week Phase 2 Results for Once-Daily Single Tablet HIV Regimen Containing Novel Prodrug Tenofovir Alafenamide (TAF)03-05-13
Tobira Therapeutics Presents Positive Phase 2b Clinical Results For Cenicriviroc in Treatment-Naïve HIV Infection in Late Breaker Session at CROI03-05-13
NanoViricides to Lead Sessions at the Symposium on Nanomedicines- Roadmap to Commercialization, in Rockville, MD tomorrow03-05-13
Resumen: El programa de EuroMedtech? 2013 cuenta con directivos especializados en dispositivos médicos03-05-13
Samenvatting: EuroMedtech 2013 programma gericht op bestuursleden medische apparatuurfabrikanten03-05-13
CircuLite® Receives Conditional IDE Approval for SYNERGY® Circulatory Support System Feasibility Trial03-05-13
Senesco Technologies Provides Corporate Update03-05-13
NPS Pharmaceuticals to Present at Barclays Capital Global Healthcare Conference03-05-13
Douglas J. Swirsky Joins Fibrocell Board03-05-13
PSI Announces Collaboration With Synta Pharmaceuticals for the GALAXY-2 Phase III Non-Small Cell Lung Cancer Trial03-05-13
Vimpat Therapeutic Role in Epilepsy Studied in New In-Demand GlobalData Report Available at MarketPublishers.com03-05-13
Targacept and AstraZeneca Amend Collaboration03-05-13
Avedro Completes $43 Million Series D Financing03-05-13
OPKO Health Completes Acquisition of Two Phase 3 Products03-04-13
Pfizer Presents Phase 3 Safety And Immunogenicity Data On Prevnar 13® In Adults With HIV03-04-13
EuroMedtech? 2013 Program Features Medical Device Executives03-04-13
Navidea Biopharmaceuticals to Announce Fourth-Quarter and Full-Year 2012 Financial Results on Wednesday, March 6, 201303-04-13
Pharma Tech Industries Selected to Manufacture Innovative Nasal Delivery System for NDA Submission03-04-13
Aphios Granted United States Patent for Zindol03-04-13
Cardiovascular Systems to Present Pivotal Orbit II Coronary Data at the 2013 American College of Cardiology Conference03-04-13
Canon U.S.A. Showcases Document Technology and Clinical Solutions at HIMSS1303-04-13
Sirtex Medical Inc. Announces Half-Year Dose Sales Report03-04-13
Advanced Cell Technology to Announce Fourth Quarter and Year-end Results on Thursday March 7th03-04-13
Genzyme's Head of Rare Diseases Honored by the Genetic Disease Foundation03-04-13
VX-787 Showed Significant Antiviral Activity and Reduced the Severity and Duration of Influenza Symptoms in Phase 2 Challenge Study03-04-13
Shape Pharmaceuticals Provides Update on SHP-141 Topical HDAC Inhibitor Clinical Development for Cutaneous T Cell Lymphoma03-04-13
Phase III Study of Teva's Milprosa? (Progesterone) Vaginal Ring Published in Fertility and Sterility03-04-13
Industry Leaders and Academic Researchers Come Together for Innovative Accelerating Cancer Cures Research Symposium03-04-13
Capital BlueCross Announces Designation of IPG as their Implantable Device Benefit Management Partner03-04-13
Targeted Medical Pharma Reports New Data on Red Blood Cell Stimulating Formulation03-04-13
Iroko Pharmaceuticals Announces Acceptance for NDA Filing of Lower Dose Submicron Diclofenac for the Treatment of Mild to Moderate Acute Pain in Adults03-04-13
Orion Bionetworks: Developing Predictive Models to Power the Search for Cures03-04-13
Cubist Announces Appointment of Michael Tomsicek to Chief Financial Officer03-04-13
FDA Accepts Biogen Idec's Biologics License Application for First Long-Lasting Factor IX Therapy for Hemophilia B03-04-13
Horizon Discovery Establishes Three New Centers of Excellence in Asia03-04-13
Horizon Discovery?????????????????3?????????03-04-13
Clinical Network Services (CNS) Appoints Leading Toxicologist Douglas Francis to BioDesk03-04-13
Medtentia International and clinicalprojects international Tap BioClinica for Express EDC, Data Management, and Centralized Imaging Reads03-04-13
PsiOxus Therapeutics Completes Patient Enrollment for Phase II Wasting Disease Therapeutic MT-10203-04-13
Idera Announces Presentation at AAD Annual Meeting Demonstrating Toll-like Receptor Antagonists Normalize Expression of Inflammatory Genes in Psoriasis Model03-02-13
KYTHERA Biopharmaceuticals, Inc. Announces Positive Interim Results from Open-Label Study of ATX-101 in the Reduction of Unwanted Submental Fat (SMF) or ?Double Chin?03-02-13
Oraya Therapy? continue à démontrer une efficacité contre la forme exsudative de la dégénérescence maculaire liée à l?âge03-01-13
Oraya-Therapie? erweist sich bei altersbedingter feuchter Makuladegeneration weiterhin als wirksam03-01-13
KLOX Technologies to Meet with Leaders in Acne During the American Academy of Dermatology Annual Meeting in Miami03-01-13
Medidata Solutions to Present at the Raymond James 34th Annual Institutional Investors Conference03-01-13
A.P. Pharma Announces Fourth Quarter and Full Year 2012 Financial Results and Highlights Recent Corporate Progress03-01-13
Osiris Therapeutics Establishes Direct Sales Force for Grafix®03-01-13
???????????????????1???????????ABILIFY MAINTENA???????? ????? ??????????????FDA????03-01-13
FDA Approves Once-Monthly ABILIFY MAINTENA? (aripiprazole) for Extended-Release Injectable Suspension for the Treatment of Schizophrenia02-28-13
Clovis Oncology Announces 2012 Operating Results and 2013 Objectives02-28-13
Anacor Pharmaceuticals Announces Positive Results from the Second Phase 3 Trial of Tavaborole for Onychomycosis02-28-13
Oraya Therapy? Continues to Show Efficacy for Wet Age-Related Macular Degeneration02-28-13
Pharma New Product Planning Teams Inject Commercial Focus During Clinical Development02-28-13
Navidea Biopharmaceuticals to Present at the Cowen & Company 33rd Annual Health Care Conference02-28-13
Hospitals, Healthcare Providers to Benefit from New Premier Agreements for Cardiac Rhythm Management Devices02-28-13
CytRx Reaches Patient Enrollment Target in Global Phase 2b Clinical Trial with Tamibarotene as First-Line Treatment for Non-Small-Cell Lung Cancer02-28-13
EnVivo Pharmaceuticals Announces Initiation of Phase 3 Clinical Trial Program of EVP-6124 in Schizophrenia02-28-13
OvaScience to Present at Cowen and Company 33rd Annual Health Care Conference02-28-13
Cognoptix begins pre-pivotal clinical trial of its drug/device test designed to identify Alzheimer's disease via beta amyloid signature in the eyes02-28-13
A.P. Pharma Appoints Jesse Hollingsworth as Vice President of Sales02-28-13
Camargo and XenoTech Present Webinar Using 505(b)(2) to Accelerate Drug Approval02-28-13
ARIAD to Present at the Cowen and Company 33rd Annual Health Care Conference02-28-13
Advaxis to Provide 2013 Business Outlook on March 6, 201302-28-13
BioLineRx's EDP-14, for Treatment of Severe and Persistent Asthma, to Enter the Company's Main Therapeutic Pipeline as BL-901002-28-13
Pacira Pharmaceuticals, Inc. Announces Timing for 2012 Financial Results Webcast and Conference Call02-28-13
Vertex meldet Einleitung eines Programms zulassungsrelevanter Studien zu VX-809 in Kombination mit Ivacaftor zur Behandlung von Patienten mit zwei Kopien der F508del-Mutation02-28-13
InVivo Therapeutics Submits Updated IDE to FDA to Begin Spinal Cord Injury Human Study02-28-13
Executive Roundtable on Adaptive Design Trials Identifies Key Factors That Dramatically Increase Development Efficiency and Productivity02-28-13
Rare disease day: Boehringer Ingelheim announces initiation of pivotal trial investigating volasertib* in patients with acute myeloid leukaemia02-28-13
NanoViricides Announces Retirement of Its Series C Convertible Preferred Stock Held by Seaside 88, LP - Company Reports Having More Than Two Years of Cash on Hand02-28-13
Vertex annonce le démarrage d?un programme pivot de Phase 3 portant sur le VX-809 pris en combinaison avec l?ivacaftor pour le traitement des personnes souffrant de fibrose kystique porteuses de deux copies de la mutation F508del02-28-13
St. Jude Medical to Present at the Barclays Global Healthcare Conference02-27-13
Raymond F. Schinazi, Ph.D., D.Sc., Joins the Vaccine & Gene Therapy Institute of Florida Board of Directors02-27-13
John Muir Health Pilots Early Warning System For Heart Attack Patients02-27-13
Acurian, the Patient Enrollment and Retention Specialist, Achieves 15-Year Milestone02-27-13
Klein Hersh Launches Innovative Branding Campaign with New Website02-27-13
Rasheda Ali on National and Local News: BrainStorm's ALS Clinical Trial Results Exceeded Expectations02-27-13
Hospitals, Healthcare Providers to Benefit from New Premier Agreements for Regional Anesthesia Trays02-27-13
Cubist Pharmaceuticals to Present at Cowen and Company 33rd Annual Health Care Conference02-27-13
Inviragen Advances DENVax into Second Stage of Ongoing Phase 2 Clinical Study02-27-13
Theorem Clinical Research Releases Booklets to Provide ICH GCP Guidance For In Vitro and Investigational Product Trials02-27-13
Samenvatting: Vertex start fase 3-programma VX-809 voor behandeling patiënten met cystische fibrose02-27-13
Resumen: Vertex inicia programa fundamental de fase 3 de VX-809 en combinación con Ivacaftor para el tratamiento de enfermos de fibrosis quística que tienen dos copias de la mutación F508del02-27-13
Verastem Cofounders to Present at MIT Technology Breakfast on Breakthrough Discoveries in Cancer Stem Cells02-27-13
Antares Pharma Announces FDA Acceptance of New Drug Application for OTREXUP?02-27-13
Genzyme Receives Company Award from European Organisation for Rare Diseases (EURORDIS)02-27-13
Riassunto: Vertex annuncia l'avvio del programma cardine di fase III condotto sul farmaco VX-809 in combinazione con ivacaftor per il trattamento di pazienti con fibrosi cistica che presentano due copie della mutazione F508del02-27-13
Hi-Tech Pharmacal to Present at the 2013 RBC Capital Markets? Healthcare Conference02-26-13
American Association of Clinical Endocrinologists, American Diabetes Association Issue Joint Response to Published JAMA Article02-26-13
Vertex Announces Initiation of Pivotal Phase 3 Program of VX-809 in Combination with Ivacaftor for the Treatment of People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation02-26-13
Crystal Pharmatech and Particle Sciences Form a US-China Pharmaceutical CRO Partnership02-26-13
Growing Body of Evidence Supports Use of DFINE's Targeted Radiofrequency Ablation? (t-RFA) for Treatment of Spinal Tumors02-26-13
Cancer Genetics, Inc. Receives Regulatory Approvals for MatBA®-DLBCL, A Proprietary Microarray Test for the Diagnosis, Prognosis, and Patient Risk Stratification of Non-Hodgkin Lymphoma02-26-13
STENTYS to Present Final Results From 1,000 Heart Attack Patient Study at ACC.1302-26-13
CytoDyn Announces Collaboration with Dr. Bruce Torbett, The Scripps Research Institute, to study PRO 140 in a Pre-exposure Prophylaxis (PrEP) Model of HIV Infection02-26-13
ClinStar to Host Live Webinar Evaluating Clinical Trial Quality in Russia and Ukraine Compared to the West and Other Emerging Markets02-26-13
Quantity and Quality of Sites is Crucial to Phase 1 Clinical Trials02-26-13
Furiex Pharmaceuticals to Present at Cowen & Company 33rd Annual Healthcare Conference02-26-13
Arrowhead Data Demonstrates RNAi Candidate ARC-520 Silences Hepatitis B Virus02-26-13
Aushon Biosystems Thrives with Increasing Demand for Personalized Medicine02-26-13
Baxter Submits Application for FDA Approval of FEIBA NF for Prophylactic Use in Hemophilia A and B Patients with Inhibitors02-26-13
Hospitals, Healthcare Providers to Benefit from New Premier Agreements for Fire, Life Safety, Security Systems and Services02-26-13
Targacept to Present at the Cowen and Company 33rd Annual Health Care Conference02-26-13
Puma Biotechnology to Present at Cowen Healthcare Conference02-26-13
Aileron Therapeutics to Highlight Stapled Peptide Pipeline at 2013 AsiaTIDES Meeting02-26-13
FDA Advisory Panel Recommends Approval of the NeuroPace RNS® System for Medically Refractory Epilepsy02-26-13
Cenduit Announces Expansion in Europe and the USA and Appoints Global Head of Technology02-26-13
Xceleron and Kinetigen Announce Partnership to Simplify and Empower Phase I Clinical Investigations02-26-13
NanoViricides, Inc. Announces that Renovation for its cGMP Clinical Drug Facility has Begun; also Addresses Shareholder Concern - Knows No Reason for the Price Drop Yesterday02-26-13
Akorn Reports 2012 Fourth Quarter and Year-End Financial Results02-26-13
Psyadon Pharmaceuticals, Inc. Announces First Patients Enrolled in Phase 3 Study of Ecopipam for the Orphan Indication Lesch-Nyhan Disease02-26-13
ImmunoCellular Therapeutics to Report Financial Results for the Fourth Quarter and Full Year 2012 on March 5, 201302-26-13
WARF???????MPEG LA?Librassay®?????????02-26-13
Furiex Receives Qualified Infectious Disease Product and Fast Track Designations from the U.S. Food and Drug Administration for Avarofloxacin (JNJ-Q2)02-25-13
Impax Laboratories Reports Fourth Quarter and Full Year 2012 Results02-25-13
CSI Presents Three-Year Orbit I Coronary Data at CRT 201302-25-13
Samenvatting: Purdue Pharma verhoogt adoptie Medidata Clinical Cloud voor versterking R&D operaties02-25-13
Resumen: Purdue Pharma aumenta la adopción de Medidata Clinical Cloud para afianzar las operaciones de I+D02-25-13
Sunovion Presents New Analyses that Continue to Support ZETONNA® (ciclesonide) Nasal Aerosol's Efficacy in SAR and PAR02-25-13
CEL-SCI Announces Initiation of New Sites for Multikine Phase III Clinical Study for Head and Neck Cancer in Taiwan02-25-13
L?approvazione di Intravase® apre il mercato vascolare di Cytori02-25-13
Goedkeuring van Intravase® opent de vasculaire markt voor Cytori02-25-13
La aprobación de Intravase® abre las puertas del mercado vascular para Cytori02-25-13
L'approbation d'Intravase® permet à Cytori de se lancer sur le marché du vasculaire02-25-13
Zulassung von Intravase® eröffnet Cytori den Markt für Gefäßprodukte02-25-13
Autoryzacja dla Intravase(R) otwiera przed Cytori rynek zabiegów naczyniowych02-25-13
Intravase® Approval Opens Vascular Market for Cytori02-25-13
Ligand Receives $1.4 Million Milestone Payment from Retrophin, Inc.02-25-13
GREER® Investigational Sublingual Allergy Immunotherapy Liquid (SAIL)? for Short Ragweed Allergies Data From Phase III Trial Featured at Allergy Meeting02-25-13
Hospitals, Healthcare Providers to Benefit from New Premier Agreements for Surgical Instruments02-25-13
LabCorp Launches Next Generation Sequencing Assay for Familial Cardiac Disease02-25-13
ReShape Medical Completes Enrollment of Pivotal Clinical Trial for Weight Loss Device02-25-13
Industry Veteran Carolyn Twomey Joins IrriMax® Corporation as Vice President, Clinical Affairs02-25-13
ReVision Optics Receives FDA Approval to Complete Enrollment in Its Phase III Clinical Trial with the Raindrop Near Vision Inlay for Improving Near Vision in Patients with Presbyopia02-25-13
DiaTech Oncology's MiCK Assay Improves Outcomes for Ovarian Cancer Patients02-25-13
PLC Systems Raises $4,040,000 in Equity Financing02-25-13
Cubist Announces Exclusive Option to Acquire Adynxx02-25-13
Purdue Pharma étend l'adoption de Medidata Clinical Cloud, afin de renforcer ses activités de recherche et de développement02-25-13
Purdue Pharma übernimmt zunehmend Clinical Cloud von Medidata zur Verstärkung von F&E-Aktivitäten02-25-13
Riassunto: Purdue Pharma amplia l'adozione delle soluzioni cloud per la gestione di sperimentazioni cliniche di Medidata per consolidare le attività di ricerca e sviluppo02-25-13
Purdue Pharma Increases Adoption of Medidata Clinical Cloud to Strengthen R&D Operations02-25-13
Research and Markets: Fatty Liver Disease Global Clinical Trials Review, H1, 201302-25-13
Intersect ENT Raises $30 Million02-25-13
Avaxia Biologics Announces First Patient Dosed in Phase 1b Study of AVX-470 in Ulcerative Colitis02-25-13
Dyax Presents DX-2930 Data at the 2013 American Academy of Allergy, Asthma and Immunology Annual Meeting02-25-13
DaVita Clinical Research Welcomes New Medical Director to Minneapolis Center02-25-13
EMD Serono: Phase III Trial of Cilengitide Did Not Meet Primary Endpoint in Patients With Newly Diagnosed Glioblastoma02-25-13
Phase III Results Showed omalizumab Significantly Reduced Disease Severity in Patients with a Chronic Form of Hives who Failed Standard Therapy02-24-13
Massachusetts Specialty Pharmacy Announces Voluntary Recall02-24-13
Phase III results: tiotropium* Respimat® is effective in symptomatic asthma patients irrespective of their allergic status02-23-13
WARF??MPEG LA?Librassay®??????02-22-13
Hospitals, Healthcare Providers to Benefit from New Premier Agreements for OR Lights and Booms02-22-13
Oxygen Biotherapeutics Enters into Definitive Agreements for Financing for up to $2.1 Million in Gross Proceeds02-22-13
Shimojani Licenses New Stroke Therapy from Niigata University02-22-13
Riassunto: Cerbomed apre nuovi mercati: da marzo in poi t-VNS con NEMOS sarà disponibile in Italia per il trattamento dell'epilessia02-22-13
Cerbomed ouvre de nouveaux marchés : à partir du mois de mars, la stimulation transcutanée du nerf vague (t-VNS), avec NEMOS, sera disponible en Italie pour le traitement des épilepsies02-22-13
Samenvatting: MPEG LA gaat door met uitbreiding Librassay met toevoeging WARF02-22-13
BioClinica, Inc. and JLL Partners, Inc. Announce Early Termination of Hart-Scott-Rodino Act Waiting Period02-21-13
Exelixis Announces Fourth Quarter and Full Year 2012 Financial Results02-21-13
Samenvatting: Cerbomed betreedt nieuwe markten: t-VNS met NEMOS voor epilepsie behandeling beschikbaar in Italië02-21-13
ICON Announces Appointment of Professor William Hall to Board of Directors02-21-13
Kinetigen to Showcase Pharmacokinetics Expertise at ASCPT Annual Meeting and Exhibition02-21-13
Samenvatting: ARIAD benoemt nieuwe algemeen directeur en bestuursleden02-21-13
TRADE NEWS: Agilent Technologies Introduces HaloPlex Exome Kits and SureCall Software02-21-13
MPEG LA continua expandindo a Librassay® com a adição da WARF02-21-13
MPEG LA setzt Ausdehnung von Librassay® mit Aufnahme von WARF fort02-21-13
MPEG LA Continúa Ampliando Librassay® con la Incorporación de la WARF02-21-13
MPEG LA poursuit son expansion de Librassay® avec l'ajout de WARF02-21-13
Riassunto: MPEG LA continua a espandere Librassay® con l'aggiunta di WARF02-21-13
MPEG LA Continues to Expand Librassay® with Addition of WARF02-21-13
Resumen: Cerbomed entra en nuevos mercados: A partir de marzo, t-VNS con NEMOS estará disponible en Italia para el tratamiento de la epilepsia02-21-13
SynapDx Corporation's CEO Stanley Lapidus Presents at Inaugural Autism Investment Conference02-21-13
LabCorp Invests $2 Million in SynapDx Corporation02-21-13
Hospitals, Healthcare Providers to Benefit from New Premier Agreements for Instrument Containers02-21-13
Research and Markets: Uveitis Global Clinical Trials Review, H1, 201302-21-13
Resumen: ARIAD anuncia el nombramiento del director general europeo y de otros miembros clave de su equipo directivo02-21-13
GenSpera Announces First Patient Treated in G-202 Phase II Hepatocellular Carcinoma Trial02-21-13
Cerbomed opens up new markets: From March on t-VNS with NEMOS will be available in Italy for the treatment of epilepsies02-21-13
Cerbomed erschließt neue Märkte: Das Therapiegerät NEMOS ist ab März auch für Epilepsiepatienten in Italien erhältlich02-21-13
Top-Line Data Show Lyrica Met Primary Endpoint in Clinical Trial as Adjunctive Therapy versus Levetiracetam in Patients with Partial Onset Seizures02-21-13
Neurovance Receives Notice of Allowance for Composition of Matter Patent and Initiates Clinical Trial of New SR Formulation of EB-102002-21-13
ACM Global Central Lab Head of R&D to Present at New Dynamics of Biomarker Labs, Central Labs and ECG & Imaging Labs in London02-21-13
Medidata Solutions Reports Full Year and Fourth Quarter 2012 Results02-21-13
GTx Provides Corporate Update and Reports 2012 Financial Results02-21-13
AXA PPP healthcare online health clinics to encourage healthier lifestyles02-21-13
Dr. Valdo Arnera, GM der PHT Corporation Europe, wird auf Veranstaltungen der Pharma- und Datenmanagementbranche über eCOA (elektronische Beurteilung klinischer Ergebnisse) referieren02-21-13
Le Directeur général de PHT Corporation pour l'Europe et Docteur en médecine, Valdo Arnera, parlera des évaluations des résultats électroniques d'essais cliniques (eCOA) lors d'événements dans l'industrie sur les produits pharmaceutiques et ...02-21-13
PHT Corporation Europe GM Valdo Arnera, MD to Speak on eCOAs (Electronic Clinical Outcome Assessments) at Pharmaceutical and Clinical Data Management Industry Events02-21-13
ARIAD meldet Ernennung des europäischen Geschäftsführers und weiterer wichtiger Mitglieder des Führungsteams02-21-13
Riassunto: ARIAD annuncia la nomina del General Manager per l'Europa e altre figure chiave del gruppo dirigente02-21-13
ARIAD annonce la nomination du directeur général européen et d'autres membres importants de la haute direction02-21-13
New findings from two studies support substantial benefit of Pradaxa® for prevention of recurrent deep vein thrombosis and pulmonary embolism02-21-13
ARIAD Announces Appointment of European General Manager and Other Key Members of Leadership Team02-21-13
Immune Initiates Bertilimumab Phase II Clinical Trial in Ulcerative Colitis02-21-13
RVC Biofund Portfolio Company to Contribute to Development of Cancer Therapy02-20-13
American Association of Clinical Endocrinologists Publishes Lipodystrophy Consensus Statement02-20-13
Hockey Players to Raise Funds to Find a Cure for Duchenne Muscular Dystrophy During Weekend Ice Duchenne Event to Benefit Cure Duchenne02-20-13
Relypsa Enrolls Initial Patient in Pivotal Phase 3 Program for the Treatment of Hyperkalemia02-20-13
Oxygen Biotherapeutics Announces Tentative Settlement of Litigation02-20-13
Symphony Clinical Research? Announces Appointment of Industry Veteran to Lead and Expand Global Clinical Operations02-20-13
ISR Report Shows Late Phase Study Conduct, Outsourcing Continues to Rise02-20-13
Samenvatting: Covidien rondt patiëntinschrijving af voor serie Iliac Stent-onderzoeken02-20-13
Samenvatting: SOV Therapeutics krijgt US Orphan Drug Designation voor gebruik 'oral testosterone undecanoate' voor behandeling groeiachterstand bij tienerjongens02-20-13
Resumen: SOV Therapeutics obtiene la designación de medicamento huérfano en Estados Unidos para el uso del undecanoato de testosterona oral en el tratamiento del retraso constitucional...02-20-13
Covidien finaliza inscrição de pacientes na série de estudos clínicos de stent ilíaco02-20-13
BSD Medical Corporation Announces Investor & Analyst Conference Call02-20-13
Covidien finaliza la inscripción de pacientes en la serie de estudios clínicos de stents ilíacos02-20-13
Covidien clôture l'inscription de patients pour sa série d'études cliniques sur les endoprothèses iliaques02-20-13
Puma Biotechnology Announces Agreement with FDA on Special Protocol Assessment for Phase III Trial of PB272 (Neratinib) in HER2-Positive Metastatic Breast Cancer Patients02-20-13
Tokai Pharmaceuticals to Participate in Upcoming Investment Conferences02-20-13
SOV Therapeutics erhält US-Zulassung als Orphan-Arzneimittel für Testosteron Undecanoat zur oralen Behandlung von körperlich bedingten Wachstums- und Pubertätsverzögerungen bei männlichen Jugendlichen (im Alter zwischen 14 und 17 Jahren)02-20-13
SOV Therapeutics obtient la désignation de médicament orphelin aux États-Unis pour l'utilisation de l'undécanoate de testostérone oral dans le traitement du retard constitutionnel de croissance et de puberté des garçons adolescents...02-20-13
Riassunto: SOV Therapeutics ottiene la designazione di farmaco orfano negli Stati Uniti per l'uso del testosterone undecanoato in formulazione orale per il trattamento del ritardo costituzionale di crescita e pubertà in adolescenti di sesso...02-20-13
SOV Therapeutics Receives US Orphan Drug Designation for the Use of Oral Testosterone Undecanoate in the Treatment of Constitutional Delay in Growth and Puberty in Adolescent Boys (14-17 Years of Age)02-20-13
Natera Launches Non-Invasive Prenatal Test PanoramaTM with Best-in-Class Sensitivity, Specificity for Detection of Fetal Chromosomal Abnormalities02-20-13
Theorem Think Tank Debuts in Boston March 702-20-13
VeriStrat® Provides Oncologists with More Information to Personalize Therapy for Elderly Patients with Lung Cancer02-20-13
Riassunto: Covidien completa l'arruolamento dei pazienti nella serie di studi clinici sullo stent iliaco02-20-13
Covidien bringt Patientenaufnahme in klinische Studienserie über Beckenarterienstents zum Abschluss02-20-13
Dyax Corp. to Participate in Upcoming 2013 Healthcare Conferences02-20-13
Covidien Completes Patient Enrollment in Iliac Stent Clinical Study Series02-20-13
Research and Markets: Inguinal Hernia Global Clinical Trials Review, H1, 201302-20-13
Research and Markets: Cancer Cachexia Global Clinical Trials Review, H1, 201302-20-13
Illumina to Webcast Live Presentation at the Cowen and Company Annual Health Care Conference02-20-13
Simcyp Adds a Pregnancy Model to its Population-Based Simulator and Includes a Scripting Facility for Customising Pharmacodynamic Response Models02-20-13
Bristol-Myers Squibb to Take Part in Citi 2013 Global Health Care Conference02-19-13
Baxano Announces Milestone in Clinical Use of iO-Flex® Technology02-19-13
Jonathan S. Helfgott, FDA Compliance Officer for Center for Drug Evaluation & Research (CDER), to Address PHT Corporation U.S. PRO & eCOA Congress02-19-13
Patient Recruitment Main Factor in Lengthy Oncology Clinical Trial Durations02-19-13
New Handheld ECG Device Helps Physicians Identify Risks for Sudden Cardiac Arrest in Young Athletes02-19-13
St. Jude Medical beginnt bahnbrechende Studie zum Thema renaler Denervierung zur Reduzierung von Herzinfarkt, Schlaganfall und Tod02-19-13
AAFS Recognizes Award-Winning Forensic Toxicologists of NMS Labs02-19-13
Laser Spine Institute Partners with Marodyne Medical to Offer the Latest in Low Intensity Vibration Science02-19-13
Cardiovascular Systems to Present Three-Year Orbit I Coronary Data at 2013 Cardiovascular Research Technologies Conference02-19-13
Hospitals, Healthcare Providers to Benefit from New Premier Agreements for OR Tables02-19-13
Navidea Biopharmaceuticals to Present at the Citi 2013 Global Healthcare Conference02-19-13
Eleven Biotherapeutics Publishes Data on EBI-005, a Novel IL-1 Inhibitor Protein for Topical Treatment of Dry Eye Disease02-19-13
PPD Commended for Excellence in Employee Training02-19-13
Rexahn Pharmaceuticals Provides Key Goals for 201302-19-13
Advaxis Announces Phase 1/2 Trial of ADXS-HPV in Anal Cancer Conducted by Brown University Oncology Group02-19-13
Osiris Therapeutics Receives Title of European Orphan Drug Designation for Prochymal®02-19-13
Concert Pharmaceuticals Announces Completion of Enrollment in Phase 2 CTP-499 Clinical Trial for the Treatment of Diabetic Kidney Disease02-19-13
Santarus to Hold Fourth Quarter and Full Year 2012 Financial Results Conference Call on March 402-19-13
PolyActiva Raises AUD$9.2M in Series B Venture Funding02-19-13
Terumo BCT??Mirasol®??????????????????????02-18-13
Research and Markets: Clinical Trial Management Systems (CTMS) - 2012 Global Strategic Business Report Profiles 75 Players02-18-13
Samenvatting: WIN Consortium en UC San Diego Moores Cancer Center werken samen aan geavanceerd, gepersonaliseerd kankermedicijn02-18-13
O consórcio WIN e o Centro de Câncer Moores da Universidade da Califórnia em San Diego passam a ser sócios em medicina avançada personalizada sobre o câncer02-18-13
WIN Consortium und UC San Diego Moores Cancer Center arbeiten in Weiterentwicklung der personalisierten Krebsmedizin als Partner zusammen02-18-13
Le Consortium WIN et University of California Moores Cancer Center San Diego (UCSD) s?associent dans le domaine de la médecine personnalisée contre le cancer02-18-13
El consorcio WIN y el Moores Cancer Center de la Universidad de California en San Diego se convierten en socios para avanzar en la medicina oncológica personalizada02-18-13
Riassunto: WIN Consortium e UC San Diego Moores Cancer Center insieme per la ricerca di trattamenti anticancro personalizzati02-18-13
The WIN Consortium and the UC San Diego Moores Cancer Center Become Partners in Advancing Personalized Cancer Medicine02-18-13
Exact Sciences Submits Second Module of Premarket Approval Application to FDA02-18-13
Genzyme Announces Positive New Data from Two Phase 3 Studies for Oral Eliglustat Tartrate for Gaucher Disease02-15-13
Samenvatting: St. Jude Medical start studie renale denervatie voor reductie hartaanval, beroerte en overlijden02-15-13
Stanford Researchers Present Data on Highly Accurate Diagnostic Test for Preeclampsia in Development by Carmenta Bioscience02-15-13
Medidata Solutions to Present at Morgan Stanley Technology, Media & Telecom Conference02-15-13
Senesco Technologies Reports Second Quarter Fiscal 2013 Financial Results02-15-13
Riassunto: St. Jude Medical dà inizio ad un importante studio sulla denervazione renale per la riduzione di infarti, ictus e mortalità02-15-13
St. Jude Medical Initiates Landmark Study of Renal Denervation for Reduction of Heart Attack, Stroke and Death02-15-13
Samenvatting: Eerste patiënt ingeschreven voor rhNGF-onderzoek naar behandeling neurotrofe keratitis02-15-13
Tokai Pharmaceuticals to Present New Galeterone Mechanism of Action Data at 2013 ASCO GU02-15-13
Resumen: Inscripción del primer paciente en el primer ensayo clínico internacional de rhNGF para el tratamiento de la queratitis neurotrófica02-15-13
Gamida Cell's NiCord® Demonstrates Successful Engraftment in Patients with Hematological Malignancies in Phase I/II Study02-14-13
BioAlliance Pharma announces the forthcoming extension of its phase II clinical trial with Validive® in the United States02-14-13
BioAlliance Pharma annonce l?extension prochaine aux Etats-Unis de son essai clinique de phase II avec Validive®02-14-13
Erster Patient in die erste internationale klinische Studie zum rhNGF für die Behandlung von neurotrophischer Keratitis aufgenommen02-14-13
Le premier patient a été recruté dans le cadre du premier essai clinique international du rhNGF pour le traitement de la kératite neurotrophique02-14-13
United Health Products Inc.'s Epic Wound Care Inc. Announces Agreement with Ryan Network for Beta Test of United's HemoStyp? Wound Care Product02-14-13
ReCor Medical begins ACHIEVE post-market study with its Generation-2, ultrasound-based PARADISE? renal denervation system02-14-13
Riassunto: Arruolato il primo paziente per il primo studio clinico internazionale sull'uso del fattore di crescita nervoso ricombinante umano (rhNGF) per il trattamento della cheratite neurotrofica02-14-13
Merck Resolves Securities Class-Action Lawsuits Related to the ENHANCE Trial02-14-13
Sirtex Medical: Interim report ? half-year ended 31 December 201202-14-13
GTx To Present Preclinical Data on a New Therapeutic Target in Prostate Cancer02-14-13
The First Patient Has Been Enrolled in the First International Clinical Trial of rhNGF for the Treatment of Neurotrophic Keratitis02-14-13
Verastem Files for Orphan Disease Status for VS-6063 in Mesothelioma02-14-13
Santarus Announces Commercial Launch of UCERIS (budesonide) Extended Release Tablets02-14-13
Incyte Reports 2012 Fourth-Quarter and Full-Year Financial Results; Provides 2013 Financial Guidance; Updates Shareholders on Key Clinical Programs02-14-13
Alexion Reports Fourth Quarter and Full Year 2012 Results02-14-13
Dr. Reddy's Q3 & 9 Months FY13 Financial Results02-14-13
Medgenics Announces Closing of Public Offering of Common Stock and Warrants02-14-13
Validation Data Presented by Natera Demonstrates Best-in-Class Specificity and Sensitivity of Non-Invasive Prenatal Test PanoramaTM at Society for Maternal-Fetal Medicine Annual Meeting02-13-13
Arrowhead Reports Fiscal 2013 First Quarter Financial Results02-13-13
Consistently Good Acute Stroke Outcomes and Device Safety With The Penumbra System? Again Confirmed In NIH-Funded Study02-13-13
Samenvatting: Gegevens van de St. Jude Medical RESPECT-studie over sluiting 'patent foramen ovale' (PFO) besproken op International Stroke Conference 201302-13-13
ProFibrix Fase III-onderzoek met FibrocapsTM (FINISH-3) passeert belangrijke veiligheidsmijlpaal; inschrijving bijna voltooid02-13-13
Cleveland HeartLab on Tour in Nashville to Bring Exclusive ? ?IT? ? Inflammation Testing to Attendees at the 2013 Country Radio Seminar02-13-13
Samenvatting: Terumo BCT meldt inschrijving 1e patiënt voor proef Mirasol Pathogeen reductiesysteem02-13-13
Terumo BCT anuncia primeiro paciente inscrito em estudo clínico norte americano do sistema tecnológico de redução dos agentes patogênicos Mirasol®02-13-13
BrainStorm to Present at the 8th Annual New York Stem Cell Summit02-13-13
NPS Pharmaceuticals to Report 2012 Financial Results02-13-13
ProFibrix Phase III Trial with FibrocapsTM (FINISH-3) Passes Important Safety Milestone & Almost Completes Enrolment02-13-13
New PROVENGE® (sipuleucel-T) Data to Be Presented at 2013 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium02-13-13
?Coming to America? Webinar Looks at Options for Foreign Drug and Device Companies02-13-13
Novel Findings from Clinical Studies Examining the Effects of Capesaris® (GTx-758) for the Treatment of Advanced Prostate Cancer to be Presented at 2013 American Society of Clinical Oncology Genitourinary Cancer Symposium02-13-13
Predictive Biosciences to Present at Key Scientific Conferences02-13-13
Samenvatting: Langetermijndata: ZYTIGA & prednison vertragen progressie prostaatkanker02-13-13
Resumen: Los datos del seguimiento de largo plazo de ZYTIGA® más prednisona siguen retrasando la evolución del cáncer de próstata metastásico resistente a la castración en pacientes que no han recibido quimioterapia02-13-13
Terumo BCT: erster Patient für nordamerikanische Studie mit Mirasol®-Pathogenreduktions-Technologiesystem angemeldet02-13-13
Terumo BCT anuncia el primer paciente inscrito en el ensayo clínico norteamericano del sistema Mirasol® de tecnología para reducción de patógenos02-13-13
Terumo BCT annonce l'inscription du premier patient de l'étude clinique Mirasol d'Amérique du Nord®, visant à évaluer le système technologique de réduction des agents pathogènes02-13-13
Acorda Therapeutics Reports Fourth Quarter and Full Year 2012 Financial Results02-13-13
Langfristigen Beobachtungsdaten zufolge verzögert ZYTIGA® zusammen mit Prednison die Progression von metastatischem kastrationsresistentem Prostatakrebs bei Patienten ohne vorherige Chemotherapie02-13-13
Les données de suivi à long terme montrent que ZYTIGA® combiné à la prednisone continue de retarder la progression du cancer de la prostate métastatique résistant à la castration chez les patients n'ayant pas reçu...02-13-13
Riassunto: I dati del follow-up a lungo termine dimostrano che ZYTIGA® associato a prednisone continua a ritardare la progressione del carcinoma metastatico prostatico resistente alla castrazione nei pazienti...02-13-13
Long-term Follow-up Data Show ZYTIGA® Plus Prednisone Continues to Delay Progression of Metastatic Castration-Resistant Prostate Cancer in Patients without Prior Chemotherapy02-13-13
Epic Sciences? Research in Prostate Cancer Presented at the 2013 ASCO Genitourinary Cancers Symposium02-12-13
AVEO and Astellas Report Final Overall Survival Results from TIVO-102-12-13
Riassunto: Terumo BCT annuncia l'iscrizione del primo paziente alla sperimentazione clinica nordamericana sul sistema tecnologico per la riduzione degli agenti patogeni Mirasol®02-12-13
Biomet Announces Enrollment in its SternaLock® Blu Clinical Trial02-12-13
MWV Healthcare analizará los avances en la distribución de fármacos sin conservantes durante Pharmapack en París02-12-13
Terumo BCT Announces First Patient Enrolled in North American Clinical Trial of Mirasol® Pathogen Reduction Technology System02-12-13
Freedom Meditech Receives FDA 510(k) Clearance for ClearPath DS-120?02-12-13
Comprehend Systems CEO Rick Morrison Leads Sessions at DIA Annual EuroMeeting and ACDM Annual Conference 201302-12-13
MWV Healthcare illustrerà gli sviluppi nella distribuzione di farmaci senza conservanti durante la conferenza Pharmapack a Parigi02-12-13
MWV Healthcare erörtert Entwicklungen bei der Verabreichung konservierungsmittelfreier Medikamente auf der Pharmapack in Paris02-12-13
MWV Healthcare bespreekt ontwikkelingen in conserveermiddelvrije verstrekking van medicijnen op Pharmapack in Parijs02-12-13
MWV Healthcare to Discuss Developments in Preservative-Free Medication Dispensing at Pharmapack in Paris02-12-13
Retrophin Raises $10.0 Million in Private Placement02-12-13
Promega Introduces MethylEdge? Bisulfite Conversion System for DNA Methylation Analysis02-12-13
ImmunoGen, Inc. Attains Patient Enrollment Milestone in IMGN901 NORTH Trial02-12-13
Lycera Enters Into a Collaboration Agreement with Merck02-12-13
Dr. Reddy's Declares Offer for OctoPlus Unconditional02-12-13
Oxygen Biotherapeutics Enters License and Supply Agreement for Dermacyte® Products with the Cosmetics Division of Valor SA02-11-13
Celgene fornece atualização regulatória do REVLIMID®02-11-13
Celgene proporciona actualización reglamentaria de REVLIMID®02-11-13
Evogen, Inc. Adds New Talent to Management Team02-11-13
Biologics, Inc. Promotes Duffy to Chief Business Development Officer02-11-13
Resumen: Los datos del ensayo clínico RESPECT de St. Jude Medical para el cierre del PFO han sido presentados durante el congreso internacional "International Stroke Conference 2013"02-11-13
La Fundación Internacional del Mieloma afirma que la innovación médica ayuda a los pacientes a vivir más tiempo y mejor02-11-13
Samenvatting: U.S. Food & Drug Administration keurt POMALYST (pomalidomide) goed voor behandeling patiënten met ziekte van Kahler02-11-13
Daten aus RESPECT-Studie zu PFO-Verschluss von St. Jude Medical auf der International Stroke Conference 2013 vorgestellt02-11-13
Samenvatting: WIN Consortium & New York University Cancer Institute verbeteren samen gepersonaliseerde kankerzorg02-11-13
TriZetto's Jeff Rideout, M.D., Among National Leaders Participating in CalPERS and White House Forums on New Care-Delivery Models02-11-13
ACT's Clinical Partner Receives FDA Approval to Initiate Clinical Trial Using the Company's hESC-derived Cells to Treat Severe Myopia02-11-13
Synta to Present at Upcoming Conferences02-11-13
WIN Consortium y el Instituto contra el Cáncer de la Universidad de Nueva York colaboran para avanzar en el tratamiento personalizado contra el cáncer02-11-13
Le consortium WIN et le New York University Cancer Institute collaborent à l'avancement de la medicine personnalisée du cancer02-11-13
O WIN Consortium e o New York University Cancer Institute colaboram para avançar o Tratamento Personalizado do Câncer02-11-13
WIN Consortium und New York University Cancer Institute arbeiten bei Weiterentwicklung der personalisierten Krebsmedizin zusammen02-11-13
Riassunto: Il New York University Cancer Institute collabora con WIN Consortium per la ricerca di trattamenti anticancro avanzati e personalizzati02-11-13
The WIN Consortium and New York University Cancer Institute collaborate to advance Personalized Cancer Care02-11-13
Riassunto: Celgene fornisce aggiornamento normativo sul REVLIMID®02-11-13
Celgene fournit une mise à jour réglementaire sur le REVLIMID®02-11-13
Celgene veröffentlicht aktuelle Mitteilung zur Zulassung von REVLIMID®02-11-13
Celgene Provides REVLIMID® Regulatory Update02-11-13
Cash Tender Offer to Acquire BioClinica, Inc. at $7.25 Per Share Commenced by an Affiliate of JLL Partners, Inc.02-11-13
Synageva BioPharma? Initiates Dosing in Phase 3 Trial of Sebelipase Alfa in Children and Adults with Late Onset LAL Deficiency02-11-13
NanoViricides to Present at the 15th Annual BIO-CEO Conference in NYC Tomorrow02-11-13
WaveMark Solution selected to Track Supplies at 70 VA Cath Labs in Real Time02-11-13
e-Therapeutics to Raise GBP 40 Million to Advance Lead Cancer Drug and Exploit Network Pharmacology Platform02-11-13
La Food and Drug Administration des États-Unis approuve POMALYST® (pomalidomide) pour le traitement des patients atteints du myélome multiple myélome multiple récurrent/réfractaire02-10-13
A Administração de Alimentos e Medicamentos dos EUA aprova o uso do medicamento POMALYST® (pomalidomida) no tratamento de pacientes com mieloma múltiplo reincidente e refratário02-10-13
La Administración de Alimentos y Medicamentos de EE.UU. aprueba POMALYST® (pomalidomida) para el tratamiento de pacientes con mieloma múltiple reincidente y refractario02-09-13
Riassunto: L'agenzia per gli alimenti e medicinali degli Stati Uniti dà la sua approvazione a POMALYST® per la cura di pazienti affetti da mieloma multiplo e in particolare in casi di refrattarietà o recidiva02-09-13
US-amerikanische FDA erteilt Zulassung für POMALYST® (Pomalidomid) zur Behandlung von Patienten mit rezidiviertem und refraktärem multiplem Myelom02-09-13
OvaScience Appoints Harald Stock to Board of Directors02-08-13
La International Myeloma Foundation afferma che l'innovazione medica sta aiutando i pazienti a vivere più a lungo e con una migliore qualità della vita02-08-13
De International Myeloma Foundation zegt dat medische innovatie patiënten helpt om een langer, beter leven te leven02-08-13
La Fondation internationale du myélome affirme que l?innovation médicale aide les patients à vivre mieux et plus longtemps02-08-13
Laut International Myeloma Foundation verhilft medizinische Innovation Patienten zu einem längeren und besseren Leben02-08-13
The International Myeloma Foundation Says Medical Innovation Is Helping Patients Live Longer, Better Lives02-08-13
Multiple Myeloma Research Foundation (MMRF) Celebrates the FDA Accelerated Approval of Pomalyst® (pomalidomide) for the Treatment of Relapsed and Refractory Multiple Myeloma02-08-13
U.S. Food and Drug Administration Approves POMALYST® (pomalidomide) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma02-08-13
Riassunto: Presentati i dati dello studio clinico RESPECT sulla chiusura del forame ovale pervio sponsorizzata da St. Jude Medical durante l'edizione 2013 dell?International Stroke Conference02-08-13
Heart Genomics Receives Loan Funding from Institute for Commercialization of Public Research02-08-13
Clinical Advantages of Critical Diagnostics? Cardiac Biomarker ST2 Featured In YouTube Video02-08-13
Trevena's Maxine Gowen named CEO of the Year by PA Bio02-08-13
Data from St. Jude Medical RESPECT Trial for PFO Closure Highlighted at International Stroke Conference 201302-08-13
New Phase 3 Data Reinforce Long-Lasting Protection from Bleeding for Patients with Hemophilia A and B02-08-13
POZEN Presents Positive PA32540 Phase 3 Data at the 2013 International Stroke Conference02-08-13
Health Care Veteran David Hall Joins Board of Directors for Compass Surgical Partners02-08-13
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2012 Financial Results02-07-13
RegeneRx Receives Notice of Allowance from Chinese Patent Office for Treatment and Prevention of Heart Disease02-07-13
St. Jude Medical annuncia l'arruolamento del primo paziente nello studio sulla denervazione renale EnligHTN II02-07-13
CorMedix Granted Extension of NYSE MKT Listing02-07-13
Dan Doctoroff, David Rubenstein, and Bloomberg Philanthropies Unveil Target ALS02-07-13
Navidea Biopharmaceuticals Announces the Presentation of Lymphoseek® Data at Upcoming Scientific Meetings02-07-13
Medidata Solutions Schedules Fourth Quarter Earnings Conference Call for February 21, 201302-07-13
ArQule, Inc. to Present at Leerink Swann Global Healthcare Conference02-07-13
Research and Markets: 2012 CRO Quality Benchmarking - Phase I Service Providers02-07-13
Acorda Therapeutics to Present at Leerink Swann Global Healthcare Conference02-07-13
Aptiv Solutions Reaches First Milestone in Delivering New Platform for Model-Based Dose-Finding Trials (ADDPLAN® DF)02-07-13
Unmet Medical Need in Treatment of Heart Failure Patients with Atrial Fibrillation Highlighted in Articles in Inaugural Issue of JACC: Heart Failure02-06-13
Work Without Limits Receives Special Recognition02-06-13
Navidea Biopharmaceuticals to Present at the 15th Annual BIO CEO & Investor Conference02-06-13
Resumen: ValveXchange, Inc. incorpora gestión para la fase de comercialización02-06-13
Solasia Announces New Executive Leadership, Clinical Activities, and China Operations02-06-13
House Wellness Foods Corporation Unveils the Immunobiotic Ingredient ?Immuno-LP20? for the North American Market02-06-13
Samenvatting: ValveXchange voegt management toe voor commercialisatiefase02-06-13
ValveXchange, Inc. étoffe son équipe de direction pour la phase de commercialisation02-06-13
BioLineRx Announces Offering of American Depositary Shares02-06-13
??????Opexa Therapeutics?Tcelna? (imilecleucel-T)?????????????????????02-06-13
Samenvatting: Overeenkomst Merck Serono en Opexa Therapeutics voor MS-therapie02-06-13
Resumen: Merck Serono y Opexa Therapeutics celebran un acuerdo de licencia y opción para el desarrollo de Tcelna TM (imilecleucel-T) para el tratamiento de la esclerosis múltiple02-06-13
SpinalCyte, LLC Reports the Addition of Jeffrey Geesin, Ph.D. to Clinical Advisory Board02-06-13
Seattle Genetics Initiates Two Phase I Trials of SGN-CD19A02-06-13
Senesco to Webcast, Live, at on February 7th02-06-13
Puma Biotechnology to Present at Leerink Swann Global Healthcare Conference02-06-13
Oxygen Biotherapeutics and the U.S. Army Institute of Surgical Research Sign a Cooperative Research and Development Agreement to Study the Effects of Oxycyte® on Ex Vivo Platelet Function02-06-13
PPD Recognized for Expertise in Clinical Research02-06-13
Derma Sciences Initiates Enrollment in DSC127 Phase 3 Trial for Healing Diabetic Foot Ulcers02-06-13
The Institute for Systems Biology and AB SCIEX Partner to Help Make Medical Care More Predictive and Personalized02-06-13
Scientific Data on PI3K/mTOR Inhibitor VS-5584 Published in Molecular Cancer Therapeutics02-06-13
BioClinica Announces Fourth Quarter and Full Year 2012 Financial Results02-06-13
Arrowhead to Report Fiscal 2013 First Quarter Financial Results02-06-13
SurModics to Webcast Annual Meeting on February 1102-06-13
Santarus to Present at Leerink Swann Global Healthcare Conference02-06-13
Bioline Launches ISOLATE II, a Precious Find for DNA and RNA Isolation02-06-13
Dyax Corp. to Participate in the Leerink Swann Global Healthcare Conference02-06-13
Biogen Idec to Acquire Full Rights and Control of TYSABRI® from Elan for Upfront Cash and Contingent Payments02-06-13
Acorda Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2012 Financial Results on February 13, 201302-06-13